The global antisense oligonucleotides market is projected to amass revenue of around USD 5,519.6 million by 2033, up from USD 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.
The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.
The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.
It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.
Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.
The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).
However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.
However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.
Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.
| Attributes | Details |
|---|---|
| Antisense Oligonucleotides Market CAGR (2023 to 2033) | 6.6% |
| Antisense Oligonucleotides Market Size (2023) | USD 2,913.5 million |
| Antisense Oligonucleotides Market Size (2033) | USD 5,519.6 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.
Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.
However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.
Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.
| Countries | Market Share (2022) |
|---|---|
| United States | 58% |
| Germany | 3.3% |
| Japan | 2.9% |
North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.
For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.
In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.
For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.
Principal Consultant
While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.
Examples:
The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.
These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.
The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.
The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.
A couple of recent developments are:
The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Robust product pipeline and rising FDA approvals in the region dominate the market.
The rising number of FDA approvals is the key opportunity in the market.
Advanced pharmacological techniques are the key trend.
Promising treatment offers for medical disorders.
The market is forecast to register a CAGR of 6.6% through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 5.1. Approved Drugs 5.2. Pegaptanib 5.3. Mipomersen 5.4. Eteplirsen 5.5. Pipeline Analysis 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Ocular Diseases 6.2. Cancer 6.3. Diabetes 6.4. Amyotrophic Lateral Sclerosis (ALS) 6.5. Duchenne Muscular Dystrophy 6.6. Spinal Muscular Atrophy 6.7. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Basic Research 7.2. Genomics 7.3. Target Validation 7.4. Drug Discovery 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Ionis Pharmaceuticals, Inc. 18.2. Sarepta Therapeutics 18.3. Biogen 18.4. Alnylam Pharmaceuticals, Inc. 18.5. Antisense Therapeutics Limited 18.6. Isarna Therapeutics GmbH 18.7. Arrowhead Pharmaceuticals, Inc. 18.8. Alantic Pharmaceuticals, Inc. 18.9. Enzon Pharmaceuticals, Inc. 18.10. Bio-Path Holdings, Inc. 18.11. Gene Signal International SA 18.12. GlaxoSmithKline plc 18.13. Geron Corporation 18.14. Grades 18.15. ICO Therapeutics 18.16. Aptose Biosciences 18.17. Marina Biotech 18.18. miRagen Therapeutics, Inc. 18.19. Synlogic, Inc. 18.20. OncoGenex Pharmaceuticals Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Antisense Oligonucleotides Market
